References
  1. Nadeem K et al. Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study. Pediatric Blood and Cancer 2019;e28044:1-7.
  2. Tong WH, Pieters R, Kaspers GJL, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123:2026-2034.Wacker P et al. Allergic Reactions to E.Coli L-Asparaginase Do Not Affect Outcome in Childhood B-precursor Acute Lymphoblastic Leukemia. A Children’s Oncology Group Study. J Pediatr Hematol Oncol 2007;29(9):627-632.
  3. Marini et al. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leukemia & Lymphoma 2019;60(12):2854-2868.
  4. U.S Department of Health and Human Services. National Cancer Institute Division of Cancer Treatment and Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50
  5. Salzer W et al. (2017). Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leukemia and Lymphoma, 1-10.
  6. Van der Sluis IM et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica 2016;101(3):279-285.
  7. Marini BL, Perissinotti AJ, Bixby DL, et al. Catalyzing improvements in ALL therapy with asparaginase. Blood Rev. 2017;31:328–338.
  8. Burke MJ, Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2017;58:540–551.
  9. Network NCC. Clinical Practice Guidelines in Oncology - Acute Lymphoblastic Leukemia. Version 1.2018. 2018.
  10. Gupta S, Rau R et al. A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy). Children’s Oncology Group.
  11. O’Brien M, McNeer J et al. A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
  12. Young D, Bowen C, Arwood N, et al. Universal Pretreatment for Asparaginase-Based Therapy Should be Standard of Care. ASPHO 2018. 2018 (Abstract 2024). [cited 2018 Oct 17]. Available from: https://aspho.planion.com/Web.User/AbstractDet?ACCOUNT1⁄4 ASPHO&ABSID1⁄413563&CONF1⁄4AM18&ssoOverride1⁄4O- FF&CKEY.
  13. Pike M, Kulkarni K, MacDonald T. Supratherapeutic levels of asparaginase: therapeutic drug monitoring experience from the Maritimes, Canada. Leukemia and Lymphoma 2019;60(9):2312-2315.